Drug-induced long QT syndrome: Concept and nonclinical models for predicting the onset of drug-induced torsade de pointes in patients in compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E14/S7B guidance

被引：1

作者：

Sugiyama, Atsushi ^{[1
,2
]}

Goto, Ai ^{[1
]}

Izumi-Nakaseko, Hiroko ^{[1
]}

Takei, Yoshinori ^{[1
,2
]}

Takahara, Akira ^{[3
]}

Kambayashi, Ryuichi ^{[1
]}

机构：

[1] Toho Univ, Fac Med, Dept Pharmacol, 5-21-16 Omori Nishi,Ota Ku, Tokyo 1438540, Japan

[2] YOKOYAMA Kazuya Canc Res Inst, Tokyo, Japan

[3] Toho Univ, Fac Pharmaceut Sci, Dept Pharmacol & Therapeut, Chiba, Japan

来源：

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | 2025年 / 392卷 / 02期

关键词：

CiPA; ICH E14/S7B Q&As; Proarrhythmic surrogate marker; QT interval; Torsade de pointes; CHRONIC ATRIOVENTRICULAR-BLOCK; III ANTIARRHYTHMIC-DRUG; FLUOROQUINOLONE ANTIBACTERIAL AGENTS; POTENTIAL DURATION PROLONGATION; REDUCES TRANSMURAL DISPERSION; ISOLATED RABBIT HEART; IN-VIVO ANALYSIS; VENTRICULAR REPOLARIZATION; TORSADOGENIC ACTION; D-SOTALOL;

D O I：

10.1124/jpet.124.002184

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) established S7B and E14 guidelines in 2005 to prevent drug-induced torsade de pointes (TdP), effectively preventing the development of high-risk drugs. However, those guidelines hampered the development of some potentially valuable drug candidates despite not being proven to be proarrhythmic. In response, comprehensive in vitro proarrhythmia assay and exposure-response modeling were proposed in 2013 to reinforce proarrhythmic risk assessment. In 2022, the ICH released E14/S7B questions and answers (stage 1), emphasizing a "double negative" nonclinical scenario for low-risk compounds. For "non-double negative" compounds, new questions and answers are expected to be enacted as stage 2 shortly, in which more detailed recommendations for proarrhythmia models and proarrhythmic surrogate markers will be provided. This review details the onset mechanisms of drug-induced TdP, including IKr inhibition, pharmacokinetic factors, autonomic regulation, and reduced repolarization reserve. It also explores the utility of proarrhythmic surrogate markers (J-T-peak, T-peak-T-end, and terminal repolarization period) besides QT interval. Finally, it presents various in silico, in vitro, ex vivo, and in vivo models for proarrhythmic risk prediction, such as comprehensive in vitro proarrhythmia assay in silico model, induced pluripotent stem cell-derived cardiomyocyte sheet, Langendorff-perfused heart preparation, chronic atrioventricular block animals (dogs, monkeys, pigs, and rabbits), acute atrioventricular block rabbits, methoxamine-sensitized rabbits, and genetically engineered rabbits for specific long QT syndromes. Those models along with the surrogate markers can play important roles in quantifying TdP risk of new compounds, impacting late-phase clinical design and regulatory decision-making, and preventing adverse events on postmarketing clinical use. Significance Statement: Since ICH S7B/E14 guidelines hampered the development of some potentially valuable compounds with unproven proarrhythmic risk, comprehensive in vitro proarrhythmia assay and exposure-response modeling were proposed in 2013 to reinforce proarrhythmic risk assessment of new compounds. In 2022, the ICH released questions and answers (stage 1), emphasizing a "double negative" nonclinical scenario for low-risk compounds, and new questions and answers (stage 2) for "non-double negative" compounds are expected. This review delves into proarrhythmic mechanisms with surrogate markers and explores various models for proarrhythmic risk prediction. (c) 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页数：19

共 128 条

[51]

Hornyik T, Castiglione A, Franke G, Perez-Feliz S, Major P, Hiripi L, Koren G, Bosze } Z, Varro A, Zehender M, Et al., Transgenic LQT2, LQT5, and LQT2-5 rabbit models with decreased repolarisation reserve for prediction of drug-induced ventricular arrhythmias, Br J Pharmacol, 177, (2020)

[52]

Iida T, Morimoto S, Amari Y, Ando T, Ichihara A, Effects of L- and N-type Ca channel blocker cilnidipine on changes in heart rate and QT interval during dialysis, Kidney Blood Press Res, 42, (2017)

[53]

Inaba H, Hayami N, Ajiki K, Sugishita Y, Kunishima T, Yamagishi N, Yamagishi S, Murakawa Y, Human atrial natriuretic peptide suppresses torsades de pointes in rabbits, Circ J, 72, (2008)

[54]

Ishizaka T, Takahara A, Iwasaki H, Mitsumori Y, Kise H, Nakamura Y, Sugiyama A, Comparison of electropharmacological effects of bepridil and sotalol in halothane-anesthetized dogs, Circ J, 72, (2008)

[55]

Iwasaki H, Takahara A, Nakamura Y, Satoh Y, Nagai T, Shinkai N, Sugiyama A, Simultaneous assessment of pharmacokinetics of pilsicainide trans-dermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs, J Pharmacol Sci, 110, (2009)

[56]

Izumi-Nakaseko H, Chiba K, Goto A, Kambayashi R, Matsumoto A, Takei Y, Kawai S, Sugiyama A, Electropharmacological characterization of licorice using the human induced pluripotent stem cell-derived cardiomyocytes sheets and the chronic atrioventricular block dogs, Cardiovasc Toxicol, 23, (2023)

[57]

Izumi-Nakaseko H, Chiba K, Hagiwara-Nagasawa M, Satsuka A, Goto A, Nunoi Y, Kambayashi R, Matsumoto A, Takei Y, Kanda Y, Et al., Optimizing the direction and order of the motion unveiled the ability of conventional monolayers of human induced pluripotent stem cell-derived cardiomyocytes to show frequency-dependent enhancement of contraction and relaxation motion, Front Cell Dev Biol, 8, (2020)

[58]

Izumi-Nakaseko H, Fujiyoshi M, Hagiwara-Nagasawa M, Goto A, Chiba K, Kambayashi R, Naito AT, Ando K, Kanda Y, Ishii I, Et al., Dasatinib can impair left ventricular mechanical function but may lack proarrhythmic effect: a proposal of non-clinical guidance for predicting clinical cardiovascular adverse events of tyrosine kinase inhibitors, Cardiovasc Toxicol, 20, (2020)

[59]

Izumi-Nakaseko H, Hagiwara-Nagasawa M, Naito AT, Goto A, Chiba K, Sekino Y, Kanda Y, Sugiyama A, Application of human induced pluripotent stem cell-derived cardiomyocytes sheets with microelectrode array system to estimate antiarrhythmic properties of multi-ion channel blockers, J Pharmacol Sci, 137, (2018)

[60]

Izumi-Nakaseko H, Kanda Y, Nakamura Y, Hagiwara-Nagasawa M, Wada T, Ando K, Naito AT, Sekino Y, Sugiyama A, Development of correction formula for field potential duration of human induced pluripotent stem cell-derived cardiomyocytes sheets, J Pharmacol Sci, 135, (2017)

← 1 2 3 4 5 6 7 8 9 10 →